Integra LifeSciences Holdings Corporation — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022, compared with the three months ended March 31, 2021. Results are unaudited and are not necessarily indicative of full-year performance. Integra operates through Codman Specialty Surgical and Tissue Technologies, providing neurosurgical, surgical instrumentation, wound reconstruction, regenerative tissue, and peripheral nerve products.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $376.6 million | $360.1 million | +4.6% |
| Gross profit | $234.1 million | $214.2 million | +9.2% |
| Gross margin | 62.1% | 59.5% | +260 bps |
| Operating income | $46.2 million | $30.7 million | +50.3% |
| Operating margin | 12.3% | 8.5% | +380 bps |
| Net income | $32.9 million | $45.4 million | -27.5% |
| Diluted EPS | $0.39 | $0.53 | -26.4% |
| Operating cash flow | $44.3 million | $69.1 million | -35.8% |
- Revenue growth reflected surgical procedure recovery, favorable private-label order timing, and contributions from the ACell portfolio. Reported revenue included a $4.6 million unfavorable foreign-exchange impact.
- Codman Specialty Surgical revenue increased 2.5% to $247.3 million; Tissue Technologies revenue increased 8.8% to $129.3 million.
- Net income declined because Q1 2021 included a $42.9 million gain from the sale of the Extremity Orthopedics business. Management stated that net income increased year over year excluding that gain.
- The effective tax rate decreased to 16.3% from 32.5%, primarily because of favorable jurisdictional income mix and a $0.8 million benefit from excess tax benefits on stock compensation.
- Cash and cash equivalents were $407.1 million at March 31, 2022, down from $513.4 million at December 31, 2021. Working capital was $750.2 million, compared with $813.7 million at year-end.
- Cash flow uses included $125.0 million for an accelerated share repurchase, $14.1 million of investing cash outflows, and $133.5 million of financing cash outflows. Capital expenditures were $9.3 million.
- Total reported borrowings included approximately $869.8 million under the Senior Credit Facility, $112.0 million under the securitization facility, and $575.0 million principal amount of convertible notes. The filing states that the Company was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Gross margin improved due to favorable product mix, lower amortization, and reduced ACell inventory step-up amortization.
- Research and development expense increased $1.7 million and selling, general and administrative expense increased $3.3 million, reflecting product development, clinical studies, EU Medical Device Regulation activities, sales investments, and other growth initiatives.
- Operating expenses increased 2.4% to $187.9 million, but declined to 49.9% of revenue from 51.0%.
- Operating cash flow decreased $24.7 million, primarily because inventory increased to support sales and accounts payable and accrued liabilities declined after payments.
- Q1 2022 included $125.0 million of accelerated share repurchases, resulting in 1.94 million shares being delivered during the quarter. The Board later authorized a new $225.0 million repurchase program expiring in December 2024.
- Special charges totaled $16.4 million in Q1 2022, compared with a net benefit of $17.3 million in Q1 2021, which included the prior-year divestiture gain.
Outlook, risks, contingencies, and unusual items
- Management expects sales and earnings over the next twelve months to be sufficient to maintain compliance with the Senior Credit Facility covenants and believes cash and available borrowings are sufficient to fund operations and capital expenditures for the foreseeable future. The filing does not provide specific full-year revenue or earnings guidance.
- COVID-19 risks remain significant, including procedure delays or cancellations, hospital staffing shortages, reduced capital spending, supply-chain disruption, higher freight costs, raw-material constraints, and labor constraints.
- The FDA has maintained its position that certain morselized amniotic membrane products do not qualify for regulation solely under Section 361; the Company discontinued manufacturing and distribution of those products before May 31, 2021.
- The TEI Boston facility remains subject to an FDA Warning Letter and a November 2021 Form 483 concerning quality-system issues. The facility’s products represented approximately 5.1% of Q1 2022 consolidated revenue. Further regulatory action could materially affect operations.
- ACell acquisition contingent consideration may reach $100 million based on revenue milestones in 2022, 2023, and 2025; its estimated fair value was $22.1 million at March 31, 2022.
- The Company incurred restructuring costs associated with employee terminations and a future plant closure. The restructuring liability was $11.1 million at March 31, 2022.
- Outstanding variable-rate debt and LIBOR-linked hedges expose the Company to interest-rate and reference-rate transition risks. The filing states that a 100-basis-point change would affect annualized interest expense on unhedged debt by approximately $1.1 million.
- Various product liability, employment, regulatory, and other claims are pending in the ordinary course. Management does not expect them to have a material adverse effect, although a particular period could be materially affected.
Important facts for investors to verify
- Whether procedure recovery and ACell-related growth persist after the favorable private-label order timing in Q1.
- Whether gross-margin improvement is sustainable after the benefits from mix and lower acquisition-related amortization.
- Progress and potential financial impact of the TEI Boston FDA remediation and any additional regulatory action.
- Inventory growth, working-capital usage, and the ability to convert earnings into operating cash flow.
- Debt maturities, covenant headroom, floating-rate exposure, and the transition away from LIBOR.
- Potential ACell, Arkis, and other acquisition-related contingent consideration payments.
- Future restructuring, EU medical-device compliance, manufacturing-transfer, and plant-closure costs.
- Execution of the repurchase program relative to liquidity, acquisitions, capital expenditures, and debt reduction priorities.